Today: 9 June 2026
Browse Category

SGX:BS6.SI 5 December 2025 - 10 February 2026

Yangzijiang Shipbuilding share price drops 2% in Singapore trade — what investors are watching next

Yangzijiang Shipbuilding share price drops 2% in Singapore trade — what investors are watching next

Yangzijiang Shipbuilding shares fell 2.1% to S$3.27 by mid-afternoon Monday, with no new company announcements. Broader market declines and a sharp drop in precious metals pressured Asian stocks. The company’s next earnings report is scheduled for March 4. Its last update in November showed a $22.8 billion order book, 71% for clean-energy vessels.
2 February 2026
··
Yangzijiang Shipbuilding (SGX: BS6) Stock Outlook: Record Order Book, Green Vessels and Fresh Analyst Upgrades in 2025

Yangzijiang Shipbuilding (SGX: BS6) Stock Outlook: Record Order Book, Green Vessels and Fresh Analyst Upgrades in 2025

Yangzijiang Shipbuilding shares traded at S$3.41–S$3.43 in Singapore midday on 5 December 2025, valuing the group at about S$13.4 billion. The stock has gained roughly 32% over the past year, backed by record earnings and a strong order book focused on clean-energy vessels. Around 70–74% of orders are for LNG or methanol dual-fuel ships. Recent volatility stems from shareholder moves and US–China trade policy shifts.
5 December 2025
·

Stock Market Today

  • Cotton Futures Hold Steady Amid Mixed Trading and Market Moves
    June 9, 2026, 9:23 AM EDT. Cotton futures showed mixed performance on Monday with 5 to 15 point gains in most contracts, except July which fell 25 points by midday. The US dollar index declined to 99.94, while crude oil prices rose by 79 cents. Weekly Commodity Futures Trading Commission (CFTC) data revealed speculative funds reduced their net long positions in cotton by 1,798 contracts to 52,402 as of June 2. The Seam reported sales of 1,311 bales at 74.00 cents per pound, while the Cotlook A Index dropped 135 points to 86.15 cents on Friday. ICE certified cotton stocks increased by 11,219 bales to 261,648 on June 5. Key futures: July cotton at 73.5 cents (down 25), December 77.59 (up 11), March 78.85 (up 5). This reflects cautious market sentiment amid variable data.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Go toTop